🇺🇸 FDA
Patent

US 10927435

Compositions for the treatment of rheumatoid arthritis and methods of using same

granted A61KA61K31/42A61K31/519

Quick answer

US patent 10927435 (Compositions for the treatment of rheumatoid arthritis and methods of using same) held by REGENERON PHARMACEUTICALS, INC. expires Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Feb 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K31/42, A61K31/519, A61K31/655, A61K39/39541